IL17A and neoplasm: Likewise, in castration-resistant prostate cancer (CRPC), Th17-type tumor-induced inflammation promotes LMP7 expression; pharmacological inhibition of LMP7 by ONX-0914 suppresses IL-17-mediated angiogenesis and EMT, thereby suppressing tumor growth (72).